Drugs & Targets MD Anderson and Generate: Biomedicines enter co-development and commercialization agreement to accelerate novel protein therapeutics for oncology using generative AI April 28, 2023Vol.49 No.17
Drugs & Targets FDA grants priority review to Lonsurf + Avastin for refractory metastatic CRC April 21, 2023Vol.49 No.16
Drugs & Targets Purdue Ventures invests in antibody-based cancer therapeutics company April 21, 2023Vol.49 No.16
Drugs & Targets mRNA cancer vaccine + Keytruda receives PRIME scheme designation from EMA for adjuvant treatment of high-risk stage 3/4 melanoma April 14, 2023Vol.49 No.15
Drugs & Targets ArteraAI and ACS form collaboration to use AI for designing personalized therapy April 14, 2023Vol.49 No.15
Drugs & Targets Adaptive Biotechnologies, Takeda form translational collaboration to measure minimal residual disease April 14, 2023Vol.49 No.15
Drugs & Targets Caris Life Sciences, Flare Therapeutics form precision oncology collaboration April 14, 2023Vol.49 No.15
Drugs & Targets University of Florida Health, Nuance Communications form collaboration focused on AI in radiology April 14, 2023Vol.49 No.15
